Moderna mFLUSIVA: FDA Clears First mRNA Flu Shot

Moderna's mFLUSIVA becomes the first FDA-approved mRNA flu vaccine, cleared Aug. 5, 2026 for adults 50 and older, lifting MRNA shares nearly 4% to $56.99.

mFLUSIVA demonstrated 26.6% greater efficacy versus standard-dose flu shots in a 40,000-person trial, the largest ever for an mRNA influenza program.
The FDA granted standard approval for adults 50–64 and accelerated approval for adults 65 and older, contingent on a postmarketing confirmatory study.
Moderna targets select U.S. retailers this fall, though meaningful commercial revenue is not expected until the second half of 2027.

Lead

Moderna received U.S. regulatory clearance on August 5, 2026, for mFLUSIVA — formerly mRNA-1010 — becoming the first messenger RNA-based seasonal influenza vaccine to win FDA approval. The authorization, covering adults 50 years of age and older, sent MRNA shares up 3.96% to $56.99 on August 6, the stock's largest single-session gain in recent months and a milestone in the company's push to expand its mRNA technology platform beyond COVID-19.

What Happened

The FDA issued two distinct approvals in a single action. Adults aged 50 to 64 received standard approval, anchored by data from a pivotal Phase 3 trial enrolling more than 40,000 participants conducted across the 2024–25 respiratory season. Adults 65 and older received accelerated approval, a pathway that permits commercial use while Moderna completes a confirmatory postmarketing study. In the trial, mFLUSIVA showed 26.6% greater relative efficacy compared with a licensed standard-dose flu vaccine, a meaningful margin in a market where incremental protection improvements translate directly to population-level outcomes.

The approval reverses a February 2026 setback in which the FDA refused to accept Moderna's original application for review — a procedural rejection that sent MRNA shares down 3.5%. The subsequent acceptance and approval within months marks a significant shift in regulatory standing for Moderna's influenza program. The branded vaccine vial, delivered by intramuscular injection, was developed and refined at Moderna lab facilities as part of the company's dedicated respiratory vaccine pipeline.

Market Reaction

MRNA traded at $56.99 on August 6, up from a prior close near $54.82, against a market capitalization of approximately $22 billion. Volume was elevated relative to the trailing 30-day average, reflecting event-driven positioning rather than a broad biotech sector move. Shares of established flu-vaccine incumbents — Sanofi, GSK, CSL Seqirus, and AstraZeneca — drew attention as the market assessed Moderna's entry into a category those firms have long dominated through legacy government supply contracts and physician relationships.

Strategic Context

The mFLUSIVA clearance carries strategic weight beyond influenza revenues. Moderna has signaled it will resubmit its combination COVID-flu mRNA vaccine following this approval — a product that would be the first bivalent mRNA respiratory shot to seek licensure. Analysts project combined U.S. sales of mFLUSIVA and a COVID-flu combination at approximately $750 million by 2030, assuming Moderna secures meaningful payer and institutional contracts over the next two procurement cycles.

The core mRNA technology advantage in influenza lies in manufacturing agility. Unlike egg-based or cell-based platforms, mRNA formulations can be redesigned and scaled more rapidly when circulating strains diverge from seasonal predictions — a chronic vulnerability in traditional flu-vaccine programs. Separate antibody data show mFLUSIVA generating stronger immune responses than Sanofi's high-dose Fluzone HD in adults 65 and older, directly challenging the segment where premium-priced shots have historically commanded the highest margins.

Competitive Landscape

Moderna enters the flu market from a standing start. The company missed the 2026 U.S. contracting cycle, which runs well ahead of the fall immunization season, pushing the first meaningful revenue contribution into the second half of 2027. Incumbents' multi-year government purchase agreements and deeply embedded pharmacy and hospital distribution networks represent structural barriers that regulatory approval alone does not dissolve. The first commercial season will function largely as a market-seeding exercise, with contracted volume expected to build materially from 2027 onward.

Outlook

mFLUSIVA's clearance validates a decade of mRNA platform investment and provides Moderna with its first regulatory anchor in a major infectious-disease market outside COVID-19. Near-term commercial traction depends on payer coverage decisions, contract negotiations, and physician adoption heading into the 2027 flu season. Longer term, the approval strengthens the regulatory pathway for Moderna's combination respiratory vaccine and sets a precedent for the company's broader pipeline ambitions in HIV, malaria, and pandemic preparedness — each of which benefits from the FDA's demonstrated willingness to approve mRNA-platform products beyond the original COVID context.

Mentioned tickers: MRNA, SNY, GSK, AZN